Search Results

Oramed Pharmaceuticals Inc. announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months.

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

Oramed Pharmaceuticals Inc. announced that on September 21, 2023, Oramed and Scilex Holding Company entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note to Oramed.

Oramed Pharmaceuticals Inc. announced that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. to establish a joint venture based on Oramed’s oral drug delivery technology.

Oramed Pharmaceuticals Inc., announced that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials.

Oramed Pharmaceuticals Inc. announced the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023.